{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Symptom+Clusters&page=14",
    "query": {
      "condition": "Symptom Clusters",
      "page": 14
    },
    "page_size": 10
  },
  "pagination": {
    "page": 14,
    "page_size": 10,
    "total_count": 16806,
    "total_pages": 1681,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Symptom+Clusters&page=15&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Symptom+Clusters&page=13&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-21T08:50:22.564Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02935465",
      "title": "Effects of Behavioral Interventions on Mechanisms of Pain Regulation and Hedonic Regulation",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Chronic, Non-neuropathic Back Pain"
      ],
      "interventions": [
        {
          "name": "Mindfulness-Oriented Recovery Enhancement (MORE)",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Support Group",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of Utah",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "21 Years to 60 Years"
      },
      "enrollment_count": 17,
      "start_date": "2016-09",
      "completion_date": "2019-06",
      "has_results": false,
      "last_update_posted_date": "2020-03-06",
      "last_synced_at": "2026-10-21T08:50:22.564Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02935465"
    },
    {
      "nct_id": "NCT03365661",
      "title": "QUILT-3.034: Non-Myeloablative TCRa/b Deplete Haplo HSCT With Post ALT-803 for AML",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "High-Risk Acute Myeloid Leukemia",
        "Treatment-Related Acute Myeloid Leukemia",
        "Secondary Acute Myeloid Leukemia",
        "Myelodysplastic Syndrome"
      ],
      "interventions": [
        {
          "name": "ALT-803",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Masonic Cancer Center, University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 0,
      "start_date": "2018-10-30",
      "completion_date": "2023-01-01",
      "has_results": false,
      "last_update_posted_date": "2018-11-09",
      "last_synced_at": "2026-10-21T08:50:22.564Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03365661"
    },
    {
      "nct_id": "NCT00045942",
      "title": "PKC412 in Participants With Acute Myeloid Leukemia or With Myelodysplastic Syndrome (CPKC412A2104 Core); and PKC412 in Participants With Acute Myeloid Leukemia or With Myelodysplastic Syndrome With Either Wild Type or Mutated FMS-like Tyrosine Kinase 3 (FLT3) (CPKC412A2104E1 and CPKC412A2104E2)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Acute Myeloid Leukemia",
        "Myelodysplastic Syndromes"
      ],
      "interventions": [
        {
          "name": "Itraconazole",
          "type": "DRUG"
        },
        {
          "name": "PKC412",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 144,
      "start_date": "2002-01-30",
      "completion_date": "2008-03-27",
      "has_results": true,
      "last_update_posted_date": "2017-08-11",
      "last_synced_at": "2026-10-21T08:50:22.564Z",
      "location_count": 4,
      "location_summary": "Los Angeles, California • Boston, Massachusetts • New York, New York",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00045942"
    },
    {
      "nct_id": "NCT05816083",
      "title": "Development and Evaluation of a Virtual Reality Tool for At-Risk Trauma-Exposed Young People",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Substance Use Disorders",
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Virtual Reality Tool",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Medical University of South Carolina",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "15 Years",
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "15 Years to 30 Years"
      },
      "enrollment_count": 50,
      "start_date": "2025-02-06",
      "completion_date": "2027-02-28",
      "has_results": false,
      "last_update_posted_date": "2026-10-20",
      "last_synced_at": "2026-10-21T08:50:22.564Z",
      "location_count": 1,
      "location_summary": "Charleston, South Carolina",
      "locations": [
        {
          "city": "Charleston",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05816083"
    },
    {
      "nct_id": "NCT00031941",
      "title": "CC-5013 in Treating Patients With Cancer That Has Not Responded to Previous Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lymphoma",
        "Small Intestine Cancer",
        "Unspecified Adult Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "lenalidomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institutes of Health Clinical Center (CC)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "2002-04",
      "completion_date": "2009-04",
      "has_results": false,
      "last_update_posted_date": "2012-03-15",
      "last_synced_at": "2026-10-21T08:50:22.564Z",
      "location_count": 2,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00031941"
    },
    {
      "nct_id": "NCT04912856",
      "title": "An Open-Label Extension of the Study XEN496 (Ezogabine) in Children With KCNQ2-DEE",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Epilepsy",
        "Epilepsy in Children",
        "Epilepsy; Seizure",
        "Disease",
        "Brain Diseases",
        "Central Nervous System Diseases",
        "Nervous System Diseases",
        "Epileptic Syndromes"
      ],
      "interventions": [
        {
          "name": "XEN496",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Xenon Pharmaceuticals Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Month",
        "maximum_age": "6 Years",
        "sex": "ALL",
        "summary": "1 Month to 6 Years"
      },
      "enrollment_count": 8,
      "start_date": "2021-08-17",
      "completion_date": "2023-11-17",
      "has_results": true,
      "last_update_posted_date": "2025-02-14",
      "last_synced_at": "2026-10-21T08:50:22.564Z",
      "location_count": 2,
      "location_summary": "Philadelphia, Pennsylvania • Tacoma, Washington",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Tacoma",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04912856"
    },
    {
      "nct_id": "NCT06854029",
      "title": "NOTRE: Optimizing Long-Acting Pre-Exposure Prophylaxis and Medications for Opioid Use Disorder Interventions in Carceral Settings",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "HIV Infections",
        "Opioid Use Disorder",
        "Incarceration; Lens"
      ],
      "interventions": [
        {
          "name": "Cabotegravir Injection",
          "type": "DRUG"
        },
        {
          "name": "Cabotegravir Pill",
          "type": "DRUG"
        },
        {
          "name": "Buprenorphine injection",
          "type": "DRUG"
        },
        {
          "name": "Buprenorphine Pill",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 450,
      "start_date": "2026-09-01",
      "completion_date": "2030-06-01",
      "has_results": false,
      "last_update_posted_date": "2026-08-26",
      "last_synced_at": "2026-10-21T08:50:22.564Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06854029"
    },
    {
      "nct_id": "NCT00365131",
      "title": "A Multicenter Study of the Efficacy of Cerezyme in Testing Skeletal Disease in Patients With Type I Gaucher Disease.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Gaucher Disease Type I",
        "Cerebroside Lipidosis Syndrome",
        "Clucocerebrosidase Deficiency Disease",
        "Glucosylceramide Beta-Glucosidase Deficiency Disease",
        "Gaucher Disease, Non-Neuronopathic Form"
      ],
      "interventions": [
        {
          "name": "Cerezyme (imiglucerase for injection)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genzyme, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "10 Years to 65 Years"
      },
      "enrollment_count": 40,
      "start_date": "1997-12",
      "completion_date": "2004-07",
      "has_results": false,
      "last_update_posted_date": "2015-03-05",
      "last_synced_at": "2026-10-21T08:50:22.564Z",
      "location_count": 1,
      "location_summary": "Coral Springs, Florida",
      "locations": [
        {
          "city": "Coral Springs",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00365131"
    },
    {
      "nct_id": "NCT02321553",
      "title": "Effect of Brown Rice on the Risk Factors for Metabolic Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Metabolic Syndrome"
      ],
      "interventions": [
        {
          "name": "Brown rice",
          "type": "OTHER"
        },
        {
          "name": "White rice",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Tufts University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 7,
      "start_date": "2014-04",
      "completion_date": "2015-02",
      "has_results": false,
      "last_update_posted_date": "2015-05-14",
      "last_synced_at": "2026-10-21T08:50:22.564Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02321553"
    },
    {
      "nct_id": "NCT06829537",
      "title": "Study of the Prevalence of Endogenous Hypercortisolism in Patients With Resistant Hypertension (MOMENTUM)",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Resistant Hypertension",
        "Hypercortisolism"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Corcept Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1143,
      "start_date": "2025-03-28",
      "completion_date": "2026-01-23",
      "has_results": false,
      "last_update_posted_date": "2026-02-17",
      "last_synced_at": "2026-10-21T08:50:22.564Z",
      "location_count": 50,
      "location_summary": "Huntington Park, California • La Jolla, California • Los Angeles, California + 42 more",
      "locations": [
        {
          "city": "Huntington Park",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Northridge",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06829537"
    }
  ]
}